Prosecution Insights
Prosecution Insights
Tech Center 3700 • Art Units: 1615 1654 3783
This examiner grants 64% of resolved cases
Aradhana Sasan is assigned to Art Unit 1615 in Tech Center 3700. The examiner has resolved 1122 cases, showing an allowance rate of 64.5 percent. This 64.5 percent rate is higher than the 26.2 percent interview lift. The median days to allowance is 1148, which defines the expected duration for successful applications. This 1148 day timeline is a critical factor for practitioners to consider when filing in Art Unit 1615.
The 26.2 percent interview lift indicates that direct communication is an effective strategy for improving the 64.5 percent baseline. With 1122 cases resolved, the data reflects a mature and stable examination style. Practitioners can use the 1148 day median to set realistic expectations for patent issuance. The 1122 case history suggests that while the allowance rate is moderate, the 26.2 percent lift offers a clear mechanism for overcoming rejections. This Tech Center 3700 examiner provides a consistent prosecution experience.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17972772 | CROMOLYN COMPOSITIONS AND METHODS THEREOF | Non-Final OA | The General Hospital Corporation |
| 18706020 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A MEROCYANINE AND DIPROPYLENE GLYCOL | Non-Final OA | L'OREAL |
| 18651013 | WATER-IN-OIL EMULSION COMPOSITION | Non-Final OA | L'OREAL |
| 18093654 | ORAL GEL COMPOSITIONS | Non-Final OA | Colgate-Palmolive Company |
| 18585371 | SUNSCREEN PREPARATION | Final Rejection | BEIERSDORF AG |
| 18692813 | Amorphous Photosensitizing Particles, Methods For The Preparation Thereof, And Methods For The Use Thereof | Non-Final OA | University of Maryland, College Park |
| 18640463 | METHOD OF PREPARING POUCH FILLING MATERIAL USING BINDER | Final Rejection | KT&G Corporation |
| 18681256 | ANTIMICROBIAL COMPOSITIONS | Non-Final OA | Firmenich SA |
| 18687161 | ANTIMICROBIAL COMBINATIONS | Non-Final OA | SYMRISE AG |
| 18564552 | CO-AMORPHOUS FORMS FOR USE IN CANCER THERAPY | Final Rejection | Zerion Pharma APS |
| 18567140 | METHODS FOR THE PULSED DELIVERY OF BIOACTIVE AGENTS | Final Rejection | David Allen PULEO |
| 18099118 | MODULATION OF NCRNAS, LYMPHOCYTES, NEUTROPHILS, INFLAMMASOMES AND P53 | Final Rejection | MUNISEKHAR MEDASANI |
| 17838636 | METHOD OF TREATING PAIN UTILIZING CONTROLLED RELEASE OXYMORPHONE PHARMACEUTICAL COMPOSITIONS AND INSTRUCTION ON DOSING FOR RENAL IMPAIRMENT | Non-Final OA | Endo Operations Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy